Economic and Social Burden of Severe Sepsis

  • E. Silva
  • D. V. Araujo


Sepsis is highly prevalent within intensive care units (ICUs) and is associated with elevated rates of morbidity and mortality [1, 2, 3], and high costs [4, 5, 6, 7]. For these reasons, healthcare providers, managers, government authorities, and insurance companies have focused their attention on strategies that could reduce the economic and social burden of sepsis. In the healthcare system, ICUs consume a considerable amount of resources and have frequently been considered the target for efforts to reduce escalating medical expenses.


Severe Sepsis Indirect Cost Septic Patient Survive Sepsis Campaign Drotrecogin Alfa 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Angus DC, Pereira CA, Silva E (2006) Epidemiology of severe sepsis around the world. Endocr Metab Immune Disord Drug Targets 6: 207–212PubMedGoogle Scholar
  2. 2.
    Silva E, Pedro MA (2004) Brazilian Sepsis Epidemiological Study (BASES study). Crit Care 8: R251–260CrossRefPubMedGoogle Scholar
  3. 3.
    Martin G S, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546–1554CrossRefPubMedGoogle Scholar
  4. 4.
    Moerer O, Schmid A, Hofmann M, et al (2002) Direct costs of severe sepsis in three German intensive care units based on retrospective electronic patient record analysis of resource use. Intensive Care Med 28: 1440–1446CrossRefPubMedGoogle Scholar
  5. 5.
    Burchardi H, Schneider H (2004) Economic aspects of severe sepsis. A review of intensive care unit costs, cost of illness and cost effectiveness of therapy. Pharmacoeconomics 22: 793–813CrossRefPubMedGoogle Scholar
  6. 6.
    Edbrooke D, Hibbert C, Ridley S, Long T, Dickie H (1999) The development of a method for comparative costing of individual intensive care units. Anaesthesia 54: 110–120CrossRefPubMedGoogle Scholar
  7. 7.
    Lee H, Doig CJ, Ghali WA, Donaldson C, Johnson D, Manns B (2004) Detailed cost analysis of care for survivors of severe sepsis. Crit Care Med 32: 981–985CrossRefPubMedGoogle Scholar
  8. 8.
    Edbrooke DL, Hibbert CL, Kingsley JM, Smith S, Bright NM, Quinn JM (1999) The patientrelated cost of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med 27: 1760–1767CrossRefPubMedGoogle Scholar
  9. 9.
    Angus DC, Linde-Zwirble WT, Lidicker J, et al (2001) Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303–1310CrossRefPubMedGoogle Scholar
  10. 10.
    Brun-Buisson C, Roudot-Thoraval F, Girou E, Grenier-Sennelier C, Durand-Zaleski I (2003) The costs of septic syndromes in the intensive care unit and influence of hospital-acquired sepsis. Intensive Care Med 29: 1464–1471CrossRefPubMedGoogle Scholar
  11. 11.
    Heyland DK, Kernerman P, Gafni A, Cook DJ (1996) Economic evaluations in the critical care literature: do they help us improve the efficiency of our unit? Crit Care Med 24: 1591–1598CrossRefPubMedGoogle Scholar
  12. 12.
    American Thoracic Society Workshop on Outcomes Research (2002) Understanding costs and cost-effectiveness in critical care. Am J Respir Crit Care Med 165: 540–550Google Scholar
  13. 13.
    Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ (2005) Methods for the Economic Evaluation of Health Care Programmes, 3rd ed. Oxford University Press, OxfordGoogle Scholar
  14. 14.
    Sefton T, Byford S, McDaid D, Hills J, Knapp M (2002) Making the Most of it: Economic Evaluation in the Social Welfare Field. Joseph Rowntree Foundation, YorkGoogle Scholar
  15. 15.
    References to obtain unit costs for pharmaceuticals and health care equipment Joint Formulary Committee. British National Formulary 52. British Medical Association and the Royal Pharmaceutical Society of Great Britain, LondonGoogle Scholar
  16. 16.
    Gold MR, Russell LB, Seigel JE, Weinstein MC (1996) Cost-effectiveness in Health and Medicine. Oxford University Press, New YorkGoogle Scholar
  17. 17.
    Braun L, Riedel AA, Cooper LM (2004) Severe sepsis in managed care: analysis of incidence, one-year mortality, and associated costs of care. J Manag Care Pharm 10: 521–530PubMedGoogle Scholar
  18. 18.
    Chalfin DB, Holbein ME, Fein AM, Carlon GC (1993) Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. JAMA 269: 549–254CrossRefGoogle Scholar
  19. 19.
    Sogayar AM, Machado FR, Rea-Neto A, et al (2008) A multicentre, prospective study to evaluate costs of septic patients in Brazilian intensive care units. Pharmacoeconomics 26: 425–434CrossRefPubMedGoogle Scholar
  20. 20.
    Cheng B, Xie G, Yao S, et al (2007) Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med 35: 2538–2546CrossRefPubMedGoogle Scholar
  21. 21.
    Schmid A, Burchardi H, Clouth J, Schneider H (2002) Burden of illness imposed by severe sepsis in Germany. Eur J Health Econ 3: 77–82CrossRefPubMedGoogle Scholar
  22. 22.
    Dellinger, RP, Levy, MM, Carlet, JM, et al (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 34: 17–60CrossRefPubMedGoogle Scholar
  23. 23.
    Bernard GR, Vincent JL, Laterre PF, et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344: 699–709CrossRefPubMedGoogle Scholar
  24. 24.
    Abraham E, Laterre PF, Garg R, et al (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353: 1332–1341CrossRefPubMedGoogle Scholar
  25. 25.
    Manns BJ, Lee H, Doig CJ, Johnson D, Donaldson C (2002) An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 347: 993–1000CrossRefPubMedGoogle Scholar
  26. 26.
    Angus DC, Linde-Zwirble WT, Clermont G, et al (2003) Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 31: 1–11CrossRefPubMedGoogle Scholar
  27. 27.
    Dhainaut JF, Payet S, Vallet B, et al (2007) Cost-effectiveness of activated protein C in real-life clinical practice. Crit Care 11: R99CrossRefPubMedGoogle Scholar
  28. 28.
    Brar SS, Manns BJ (2007) Activated protein C: cost-effective or costly? Crit Care 11: 164CrossRefPubMedGoogle Scholar
  29. 29.
    Fowler RA, Hill-Popper M, Stasinos J, Petrou C, Sanders GD, Garber AM (2003) Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis. J Crit Care 18: 181–191CrossRefPubMedGoogle Scholar
  30. 30.
    Neilson AR, Burchardi H, Chinn C, Clouth J, Schneider H, Angus D (2003) Cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in Germany. J Crit Care 18: 217–227CrossRefPubMedGoogle Scholar
  31. 31.
    Betancourt M, McKinnon PS, Massanari RM, Kanji S, Bach D, Devlin JW (2003) An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures. Pharmacoeconomics 21: 1331–1340CrossRefPubMedGoogle Scholar
  32. 32.
    Shorr AF, Micek ST, Jackson WL Jr, Kollef MH (2007) Economic implications of an evidencebased sepsis protocol: can we improve outcomes and lower costs? Crit Care Med 35: 1257–1262CrossRefPubMedGoogle Scholar
  33. 33.
    Talmor D, Greenberg D, Howell MD, Lisbon A, Novack V, Shapiro N (2008) The costs and cost-effectiveness of an integrated sepsis treatment protocol. Crit Care Med 36: 1168–1174CrossRefPubMedGoogle Scholar
  34. 34.
    Rivers E, Nguyen B, Havstad S, et al (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345: 1368–1377CrossRefPubMedGoogle Scholar
  35. 35.
    Talmor D, Shapiro N, Greenberg D, Stone PW, Neumann PJ (2006) When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature. Crit Care Med 34: 2738–2747CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • E. Silva
    • 1
  • D. V. Araujo
    • 2
  1. 1.Intensive Care UnitHospital Albert EinsteinSao Paulo, SPBrazil
  2. 2.Department of Internal Medicine Medical Sciences SchoolUniversidade do Estado do Rio de JaneiroRio de JaneiroBrazil

Personalised recommendations